Daniela Vilasboas-Campos obtained a M.Sc. in Plant Molecular Biology, Biotechnology and Bioentrepreneurship (2018) at the University of Minho. She has developed her master’s thesis work at the Life and Health Sciences Research Institute (ICVS) dedicated to the evaluation of antioxidant and neuroprotective effects of medicinal plant extracts in C. elegans models of tauopathy and polyglutamine disease. In 2018, she integrated the EXOS3 collaborative research project with the aim of identifying novel disease-modifying genes and pathways of MJD/SCA3 patients, using a whole-exome approach. Daniela Vilasboas-Campos is currently an PhD student in Health Sciences, integrated in the Translational Neurogenetics research team, at ICVS, School of Medicine at the University of Minho. In 2019, she was awarded an individual PhD fellowship financed by the Portuguese Foundation for Science and Technology (FCT) with a project focusing on chemogenomics screening for novel therapeutic target identification in a C. elegans model of MJD/SCA3. The lack of effective therapeutic strategies for MJD/SCA3 motivates her to perform large-scale phenotype-based drug and genetic screenings in C. elegans, aiming at identifying novel molecules and therapeutic targets. Therefore, she established an automated assay to screen for molecules able to act as enhancers of protein-folding and homeostasis capacity. Currently, she is dedicated to testing several therapeutic approaches in collaborations with various pharmaceutical companies, screening libraries of novel and repurposed compounds and identifying genetic modifier pathways that can provide targets for new drug development, offering new therapeutic possibilities for MJD/SCA3 patients. Vilasboas-Campos has published 5 scientific articles to date (two as first-author and three as co-author) in international peer-reviewed journals.